Short Interest in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Drops By 47.5%

Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 1,460,000 shares, a decrease of 47.5% from the January 31st total of 2,780,000 shares. Based on an average trading volume of 2,750,000 shares, the short-interest ratio is currently 0.5 days. Approximately 5.9% of the company's stock are sold short.

Analyst Ratings Changes

Separately, D. Boral Capital began coverage on Tevogen Bio in a report on Tuesday. They issued a "buy" rating and a $10.00 price objective for the company.

Tevogen Bio Price Performance

Shares of NASDAQ:TVGN traded up $0.22 during trading on Tuesday, hitting $1.40. The company's stock had a trading volume of 383,205 shares, compared to its average volume of 2,802,305. The company has a 50-day moving average of $1.35 and a 200-day moving average of $1.14. Tevogen Bio has a 12 month low of $0.26 and a 12 month high of $8.49.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. HGC Investment Management Inc. bought a new stake in Tevogen Bio during the 3rd quarter worth approximately $82,000. Geode Capital Management LLC grew its position in shares of Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after purchasing an additional 107,566 shares in the last quarter. XTX Topco Ltd bought a new stake in Tevogen Bio during the 4th quarter valued at approximately $55,000. China Universal Asset Management Co. Ltd. purchased a new stake in Tevogen Bio during the 4th quarter valued at approximately $38,000. Finally, JPMorgan Chase & Co. raised its position in shares of Tevogen Bio by 74.2% during the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after buying an additional 16,695 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.